{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:02:59Z","timestamp":1792202579325,"version":"4.4.0"},"reference-count":111,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Thalassemia syndromes are characterized by the inability to produce normal hemoglobin. Ineffective erythropoiesis and red cell transfusions are sources of excess iron that the human organism is unable to remove. Iron that is not saturated by transferrin is a toxic agent that, in transfusion-dependent patients, leads to death from iron-induced cardiomyopathy in the second decade of life. The availability of effective iron chelators, advances in the understanding of the mechanism of iron toxicity and overloading, and the availability of noninvasive methods to monitor iron loading and unloading in the liver, heart, and pancreas have all significantly increased the survival of patients with thalassemia. Prolonged exposure to iron toxicity is involved in the development of endocrinopathy, osteoporosis, cirrhosis, renal failure, and malignant transformation. Now that survival has been dramatically improved, the challenge of iron chelation therapy is to prevent complications. The time has come to consider that the primary goal of chelation therapy is to avoid 24-h exposure to toxic iron and maintain body iron levels within the normal range, avoiding possible chelation-related damage. It is very important to minimize irreversible organ damage to prevent malignant transformation before complications set in and make patients ineligible for current and future curative therapies. In this clinical case-based review, we highlight particular aspects of the management of iron overload in patients with beta-thalassemia syndromes, focusing on our own experience in treating such patients. We review the pathophysiology of iron overload and the different ways to assess, quantify, and monitor it. We also discuss chelation strategies that can be used with currently available chelators, balancing the need to keep non-transferrin-bound iron levels to a minimum (zero) 24 h a day, 7 days a week and the risk of over-chelation.<\/jats:p>","DOI":"10.3390\/ijms21228771","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T09:46:18Z","timestamp":1605865578000},"page":"8771","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8375-6289","authenticated-orcid":false,"given":"Valeria","family":"Pinto","sequence":"first","affiliation":[{"name":"Centro della Microcitemia e delle Anemie Congenite Ente Ospedaliero Ospedali Galliera, Via Volta 6, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian","family":"Forni","sequence":"additional","affiliation":[{"name":"Centro della Microcitemia e delle Anemie Congenite Ente Ospedaliero Ospedali Galliera, Via Volta 6, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"2008","author":"Modell","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2018-06-818187","article-title":"How I manage medical complications of \u03b2-thalassemia in adults","volume":"132","author":"Taher","year":"2018","journal-title":"Blood"},{"key":"ref_5","unstructured":"Cappellini, M.D., Cohen, A., Porter, J., Taher, A., and Viprakasit, V. (2014). Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT), Thalassaemia International Federation. [3rd ed.]."},{"key":"ref_6","unstructured":"Taher, A., Musallam, K., and Cappellini, M. (2017). Guidelines for the Management of Non-Transfusion Dependent Thalassaemias, Thalassaemia International Federation. [2nd ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"ref_8","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Rugolotto","year":"2004","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1196\/annals.1345.006","article-title":"Survival and Complications in Thalassemia","volume":"1054","author":"Cappellini","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.284.6322.1081","article-title":"Survival and desferrioxamine in thalassaemia major","volume":"284","author":"Modell","year":"1982","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-07-2933","article-title":"Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05202.x","article-title":"Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance","volume":"127","author":"Anderson","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ajh.22247","article-title":"Pituitary iron and volume predict hypogonadism in transfusional iron overload","volume":"87","author":"Noetzli","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12968-017-0349-3","article-title":"Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia","volume":"19","author":"Kirk","year":"2017","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2009-06-225615","article-title":"Pancreatic iron loading predicts cardiac iron loading in thalassemia major","volume":"114","author":"Noetzli","year":"2009","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bjh.13374","article-title":"Estimating tissue iron burden: Current status and future prospects","volume":"170","author":"Wood","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/asheducation-2014.1.210","article-title":"Guidelines for quantifying iron overload","volume":"2014","author":"Wood","year":"2014","journal-title":"Hematology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1532-429X-10-42","article-title":"Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance","volume":"10","author":"Modell","year":"2008","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2141.1995.tb08351.x","article-title":"Relationship between transfusion regimen and suppression of erythropoiesis in \u03b2-thalassaemia major","volume":"89","author":"Cazzola","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/ajh.22102","article-title":"Changing patterns of splenectomy in transfusion-dependent thalassemia patients","volume":"86","author":"Piga","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_22","first-page":"4","article-title":"Red blood cell alloimmunisation in transfusion-dependent thalassaemia: A systematic review","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/MOH.0000000000000373","article-title":"Is there a standard-of-care for transfusion therapy in thalassemia?","volume":"24","author":"Franchini","year":"2017","journal-title":"Curr. Opin. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3324\/haematol.2009.012393","article-title":"Pregnancy and \u03b2-thalassemia: An Italian multicenter experience","volume":"95","author":"Origa","year":"2010","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100594","DOI":"10.1016\/j.blre.2019.100594","article-title":"Management of the aging beta-thalassemia transfusion-dependent population\u2014The Italian experience","volume":"38","author":"Pinto","year":"2019","journal-title":"Blood Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/nyas.13060","article-title":"Management of iron overload in hemoglobinopathies: What is the appropriate target iron level?","volume":"1368","author":"Coates","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.freeradbiomed.2014.10.861","article-title":"Iron toxicity and its possible association with treatment of Cancer: Lessons from hemoglobinopathies and rare, transfusion-dependent anemias","volume":"79","author":"Puliyel","year":"2015","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/jech-2014-205075","article-title":"Thalassaemia and risk of cancer: A population-based cohort study","volume":"69","author":"Chung","year":"2015","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/bjh.13009","article-title":"Hepatocellular carcinoma in thalassaemia: An update of the Italian Registry","volume":"167","author":"Garani","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/03630269.2011.588355","article-title":"Malignancies in \u03b2-Thalassemia Patients: First Description of Two Cases of Thyroid Cancer and Review of the Literature","volume":"35","author":"Poggi","year":"2011","journal-title":"Hemoglobin"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1182\/blood-2011-03-283614","article-title":"\u03b2-thalassemia: A model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism","volume":"118","author":"Ginzburg","year":"2011","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3324\/haematol.10842","article-title":"Liver iron concentrations and urinary hepcidin in -thalassemia","volume":"92","author":"Origa","year":"2007","journal-title":"Haematology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.freeradbiomed.2014.03.039","article-title":"Physiology and pathophysiology of iron in hemoglobin-associated diseases","volume":"72","author":"Coates","year":"2014","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/asheducation-2017.1.265","article-title":"Iron overload in thalassemia: Different organs at different rates","volume":"2017","author":"Taher","year":"2017","journal-title":"Hematology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/hematology.2019000036","article-title":"Iron overload in transfusion-dependent patients","volume":"2019","author":"Coates","year":"2019","journal-title":"Hematology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.2009.07970.x","article-title":"Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major","volume":"148","author":"Farmaki","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2010.08229.x","article-title":"New golden era of chelation therapy in thalassaemia: The achievement and maintenance of normal range body iron stores","volume":"150","author":"Kolnagou","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14575","article-title":"How we manage iron overload in sickle cell patients","volume":"177","author":"Coates","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ijlh.12505","article-title":"The mutual control of iron and erythropoiesis","volume":"38","author":"Camaschella","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.21626","article-title":"Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients","volume":"85","author":"Taher","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.12484","article-title":"No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia","volume":"93","author":"Origa","year":"2008","journal-title":"Haematologica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2141.2012.09152.x","article-title":"Neridronate improves bone mineral density and reduces back pain in \u03b2-thalassaemia patients with osteoporosis: Results from a phase 2, randomized, parallel-arm, open-label study","volume":"158","author":"Forni","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00277-012-1465-7","article-title":"A national registry of haemoglobinopathies in Greece: Deducted demographics, trends in mortality and affected births","volume":"91","author":"Voskaridou","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2013.083634","article-title":"The Myocardial Iron in Thalassemia (MINT) Investigators International survey of T2* cardiovascular magnetic resonance in -thalassemia major","volume":"98","author":"Carpenter","year":"2013","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIR.0b013e31829b2be6","article-title":"American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular Function and Treatment in \u03b2-Thalassemia Major: A consensus statement from t","volume":"128","author":"Pennell","year":"2013","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ajh.21398","article-title":"The influence of treatment in specialized centers on survival of patients with thalassemia major","volume":"84","author":"Forni","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bcmd.2012.10.006","article-title":"Combined chelation therapy with deferasirox and deferoxamine in thalassemia","volume":"50","author":"Lal","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V122.21.2257.2257","article-title":"Deferasirox\u2013Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)","volume":"122","author":"Aydinok","year":"2013","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.2011.08626.x","article-title":"Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies","volume":"154","author":"Voskaridou","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200008033430503","article-title":"Correction: Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major","volume":"343","author":"Angelucci","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood-2007-08-109306","article-title":"Effect of transfusional iron intake on response to chelation therapy in \u03b2-thalassemia major","volume":"111","author":"Cohen","year":"2008","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/ajh.24911","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies","volume":"92","author":"Origa","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1388-9842(03)00102-8","article-title":"Typical manifestation of acute congestive heart failure in patients with Thalassaemia major causing diagnostic delay in the emergency room","volume":"5","author":"Forni","year":"2003","journal-title":"Eur. J. Hear. Fail."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ejechocard\/jeq190","article-title":"Clinical management of cardiovascular complications in patients with thalassaemia major: A large observational multicenter study","volume":"12","author":"Derchi","year":"2011","journal-title":"Eur. J. Echocardiogr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1515\/jpem-2006-190404","article-title":"Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia","volume":"19","author":"Roos","year":"2006","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/ajh.23844","article-title":"Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with \u03b2-thalassemia major","volume":"89","author":"Casale","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/nyas.13041","article-title":"Management of beta-thalassemia-associated osteoporosis","volume":"1368","author":"Giusti","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2006.06203.x","article-title":"Effect of enhanced iron chelation therapy on glucose metabolism in patients with \u03b2-thalassaemia major","volume":"134","author":"Farmaki","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1002\/ajh.25009","article-title":"Lack of correlation between heart, liver and pancreas MRI-R2*: Results from long-term follow-up in a cohort of adult \u03b2-thalassemia major patients","volume":"93","author":"Pinto","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bcmd.2015.08.004","article-title":"Klotho, a new marker for osteoporosis and muscle strength in \u03b2-thalassemia major","volume":"55","author":"Baldan","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2019-125822","article-title":"Erythroferrone Regulates Bone Remodeling in \u03b2-Thalassemia","volume":"134","author":"Martinez","year":"2019","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.ajkd.2009.03.013","article-title":"Fanconi Syndrome Due to Deferasirox","volume":"54","author":"Rafat","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.25122","article-title":"Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent \u03b2-thalassemia and other anemias","volume":"93","author":"Origa","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjh.13217","article-title":"Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent \u03b2 thalassaemia","volume":"168","author":"Piga","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood-2019-130237","article-title":"Iron Chelation and Ferritin below 500 Mcg\/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials","volume":"134","author":"Scaramellini","year":"2019","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2008.11.001","article-title":"Hepatic iron overload and hepatocellular carcinoma","volume":"286","author":"Kew","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.gastro.2004.09.019","article-title":"Iron, hemochromatosis, and hepatocellular carcinoma","volume":"127","author":"Kowdley","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1572-0241.2005.41287.x","article-title":"Duration of Hepatic Iron Exposure Increases the Risk of Significant Fibrosis in Hereditary Hemochromatosis: A New Role for Magnetic Resonance Imaging","volume":"100","author":"Olynyk","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0037-1963(01)90060-5","article-title":"Progression of iron overload in sickle cell disease","volume":"38","author":"Olivieri","year":"2001","journal-title":"Semin. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1179\/1607845413Y.0000000120","article-title":"A killer revealed: 10-year experience with beta-thalassemia intermedia","volume":"19","author":"Matta","year":"2014","journal-title":"Hematology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2011.049957","article-title":"Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with \u03b2-thalassemia major","volume":"97","author":"Pennell","year":"2012","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","article-title":"A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in \u03b2-thalassemia major (CORDELIA)","volume":"123","author":"Pennell","year":"2014","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","article-title":"Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years\u2019 follow-up","volume":"118","author":"Cappellini","year":"2011","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/bjh.12340","article-title":"Assessment and management of iron overload in \u03b2-thalassaemia major patients during the 21st century: A real-life experience from the Italian Webthal project","volume":"161","author":"Piga","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/j.gastro.2011.06.065","article-title":"Improvement in Liver Pathology of Patients With \u03b2-Thalassemia Treated With Deferasirox for at Least 3 Years","volume":"141","author":"Deugnier","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1196\/annals.1345.043","article-title":"Monitoring Long-Term Efficacy of Iron Chelation Treatment with Biomagnetic Liver Susceptometry","volume":"1054","author":"Fischer","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/mrm.23148","article-title":"Measurement of liver iron overload: Noninvasive calibration of MRI-R2* by magnetic iron detector susceptometer","volume":"67","author":"Gianesin","year":"2012","journal-title":"Magn. Reson. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1109\/TBME.2010.2053204","article-title":"Total Iron-Overload Measurement in the Human Liver Region by the Magnetic Iron Detector","volume":"57","author":"Marinelli","year":"2010","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11547-016-0661-2","article-title":"Comparison between different software programs and post-processing techniques for the MRI quantification of liver iron concentration in thalassemia patients","volume":"121","author":"Bacigalupo","year":"2016","journal-title":"La Radiol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12968-014-0062-4","article-title":"Calibration of myocardial T2 and T1 against iron concentration","volume":"16","author":"Carpenter","year":"2014","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.110.007641","article-title":"On T2* Magnetic Resonance and Cardiac Iron","volume":"123","author":"Carpenter","year":"2011","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11739-018-1890-2","article-title":"Risk factors for heart disease in transfusion-dependent thalassemia: Serum ferritin revisited","volume":"14","author":"Derchi","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2012-02-412692","article-title":"Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study","volume":"120","author":"Taher","year":"2012","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"E135","DOI":"10.1002\/ajh.25075","article-title":"MRI for the diagnosis of cardiac and liver iron overload in patients with transfusion-dependent thalassemia: An algorithm to guide clinical use when availability is limited","volume":"93","author":"Viprakasit","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.V100.1.17","article-title":"Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation","volume":"100","author":"Angelucci","year":"2002","journal-title":"Blood"},{"key":"ref_89","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Haematologica"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40273-013-0076-z","article-title":"Cost\u2013Utility Analysis of Deferiprone for the Treatment of \u03b2-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective","volume":"31","author":"Bentley","year":"2013","journal-title":"PharmacoEconomics"},{"key":"ref_91","unstructured":"Novartis Pharmaceuticals UK Ltd. (2018, March 01). Exjade\u00ae 125 mg, 250 mg, 500 mg Dispersible Tablets Summary of Product Characteristics. Available online: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000670\/human_med_000780.jsp&mid=WC0b01ac058001d124."},{"key":"ref_92","unstructured":"Novartis Pharmaceuticals Corporation (2018, March 01). Exjade\u00ae (Deferasirox) Tablets, for Oral Suspension Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/%0Adrugsatfda_docs\/label\/2016\/021882s024lbl.pdf%0A."},{"key":"ref_93","unstructured":"Novartis Pharma Stein AG (2018, March 01). Desferal\u00ae (Deferoxamine Mesilate) Product Label, Available online: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?%0Aevent=overview.process&ApplNo=016267%0A."},{"key":"ref_94","unstructured":"ApoPharma Inc. (2018, March 01). Ferriprox\u00ae (Deferiprone) Tablets for Oral Use Prescribing Information, Available online: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/%0Aindex.cfm?event=overview.process&ApplNo=021825."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2019-125575","article-title":"A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade\u00ae) in Patients with Low\/Intermediate-1 Risk MDS at the Beginning of Transfusional Story","volume":"134","author":"Angelucci","year":"2019","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2014-07-586677","article-title":"Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload","volume":"125","author":"Aydinok","year":"2015","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.11414","article-title":"A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major","volume":"92","author":"Aydinok","year":"2007","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/bjh.14712","article-title":"The new era of chelation treatments: Effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major","volume":"178","author":"Maggio","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"E338","DOI":"10.1002\/ajh.25222","article-title":"Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients","volume":"93","author":"Pinto","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/nyas.13027","article-title":"Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major","volume":"1368","author":"Angelucci","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2012.06.001","article-title":"Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with \u03b2-thalassemia intermedia","volume":"49","author":"Musallam","year":"2012","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.thromres.2012.07.013","article-title":"Cerebral infarction in \u03b2-thalassemia intermedia: Breaking the silence","volume":"130","author":"Musallam","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.3324\/haematol.2013.097220","article-title":"Serum ferritin level and morbidity risk in transfusion-independent patients with \u03b2-thalassemia intermedia: The ORIENT study","volume":"99","author":"Musallam","year":"2014","journal-title":"Haematologica"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.113.002124","article-title":"Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of \u03b2-Thalassemia Patients Using Right Heart Catheterization","volume":"129","author":"Derchi","year":"2014","journal-title":"Circulation"},{"key":"ref_105","unstructured":"Taher, A., Vichinsky, E., Musallam, K., Cappellini, M., and Viprakasit, V. (2013). Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT), Thalassaemia International Federation."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/ajh.24628","article-title":"Serum ferritin values between 300 and 800 ng\/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable","volume":"92","author":"Saliba","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major","volume":"331","author":"Brittenham","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1111\/j.1537-2995.2007.01416.x","article-title":"Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review","volume":"47","author":"DeLea","year":"2007","journal-title":"Transfusion"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of Long-Term Iron-Chelating Therapy","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.12517","article-title":"Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major","volume":"163","author":"Origa","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2019-128320","article-title":"Selecting \u00df-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm","volume":"134","author":"Baronciani","year":"2019","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/22\/8771\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:34:45Z","timestamp":1760178885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/22\/8771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":111,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21228771"],"URL":"https:\/\/doi.org\/10.3390\/ijms21228771","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]}}}